Peripherally located smaller HCC tumours are most likely to experience a > 90% or complete tumour necrosis after TACE. Surprisingly, arterial-phase enhancement and portal venous-phase washout were not significantly predictive of TACE-induced tumour necrosis. The TACE response was not statistically associated with improved survival.
Aims
Myeloid sarcoma (MS) is a rare extramedullary neoplasm composed of immature myeloid precursor cells thought to be a unique clinical presentation of acute myeloid leukaemia (AML). Like AML, MS has a poor prognosis, but due to the rare nature of MS there are limited studies examining potential prognostic factors. We report our institutional experience, with the aim of investigating and establishing salient clinicopathological and molecular features of MS.
Methods and results
We retrospectively examined all clinicopathological and molecular data on MS patients between 2001 and 2017 from the University of Alabama at Birmingham (UAB) electronic medical records. The UAB electronic medical records were also reviewed and compared with the literature for other potential prognostic factors. Sixty‐three patients were included in the study. The median overall survival was 24 months in the group with normal karyotype and 12 months in patients with an abnormal karyotype.
Conclusions
We found that an abnormal karyotype was associated with a statistically significant worse prognosis.
The requirement for repeat TACE is associated with older age, increased HCC tumour burden and subtotal TACE-induced HCC necrosis. Importantly, repeat TACE was not associated with reduced survival.
A 30-year-old woman at 33.4 weeks of gestation who had a history of gestational diabetes was admitted for acute epigastric pain and respiratory distress. On admission, her triglyceride (TG) level was 7716 mg/dL, total cholesterol was 1638 mg/dL, lipase was 349 U/L, and amylase was 208 U/L; thus, she was diagnosed with acute pancreatitis. Because pharmacologic treatment options for hypertriglyceridemia are limited in pregnancy, therapeutic plasma exchange (TPE) was performed emergently to acutely decrease the level of TGs in the Labor and Delivery Unit, with full support from the Obstetrical Service in case emergency delivery was necessary ( Fig. A shows her lipemic plasma compared with nonlipemic plasma from a control patient in Fig. B). Briefly, the plasma component containing TG is separated extracorporeally by centrifugation and is replaced by 5% albumin as the replacement fluid, as in this case. Other inflammatory cytokines may also be removed during the process. 1 Furthermore, several changes during pregnancy should be considered. For example, plasma volume (PV) can increase by 10 to 15% by the second half of the first trimester, further expanding through 30 to 34 weeks; therefore, accounting for this fact, we calculated the blood volume based on Nadler's formula and exchanged 1.5 PVs in this patient. [2][3][4] Low resistance in the uteroplacental circulation and other vessels contributes to a total decline in vascular resistance, so replacement fluids should be readily available for procedure-induced hypotension, if needed. 5 Finally, although heparin may release lipoprotein lipase that enhances TG clearance, and although pregnancy is a hypercoagulable state, we elected to use citrate as the anticoagulation during TPE, because the procedure also removes coagulation factors and thus may predispose the patient to an increased bleeding risk. 6 After two procedures, her TGs decreased to 750 mg/dL. She was then started on a low-fat diet and omega-3-acid ethyl esters for lipid control for the remainder of her pregnancy, with a goal TG <1000 mg/dL. Another TPE was performed 16 days later, because her TGs had increased to 974 mg/dL (Fig. C shows the relationship between TG level and TPEs). She From the
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.